SAE0171

Sigma-Aldrich

Angiotensin Converting Enzyme-2, ACE2

biotin-tagged, human recombinant, ≥1000000U/mg, expressed in HEK 293 cells

Synonym(s):
ACE2, Metalloprotease MPROT15, SARS-COV2 receptor, Angiotensin-converting enzyme homolog (ACEH), ACE-related carboxypeptidase, COVID-19 receptor

recombinant

expressed in HEK 293 cells

Quality Level

description

Biotinylation: ≥90% (gel shift assay)

assay

≥95% (SDS-PAGE)

specific activity

≥1000000 U/mg

shipped in

wet ice

storage temp.

−20°C

General description

Angiotensin Converting Enzyme-2 (ACE2) is a membrane-associated and secreted enzyme that is principally expressed on endothelium. In humans, ACE2 occurs mainly in endothelium of heart, kidney, and testis, with other expression in coronary vessel smooth muscle and kidney tubular epithelium ACE2 is a component of the renin-angiotensin system (RAS) that provides protective effects in peripheral tissues.
Coronaviruses such as SARS-CoV-2 and SARS-CoV-1 use the host ACE2 as a co-receptor to gain intracellular entry into the lungs and brain. The virion expresses a protein termed spike, which directly binds to the extracellular domain of ACE2. A specific region in the spike protein serves as the receptor binding domain (RBD). The ACE2:spike interaction has a high affinity of 15 nM.

Recombinant human ACE2 is expressed in human HEK 293 cells as a glycoprotein with a C-terminal FLAG® tag and his-tag with a calculated molecular mass of 85.9 kDa. The DTT-reduced protein migrates as a 90–120 kDa polypeptide on SDS-PAGE due to glycosylation.

This ACE2 is labelled with biotin, to form Angiotensin Converting Enzyme-2. This ACE2 biotin-tagged may serve as a useful tool for binding experiments while detecting protein: protein interaction assays using binding partners such as CoV spike protein. The degree of biotinylation is ≥90%. This ACE2-biotin can be visualized with streptavidin-conjugated probes (e.g., Streptavidin, HRP conjugate catalog No. 18-152).

Application

  • Exploration of the protein protein interaction of ACE2 with is partners, like COV Spike protein.
  • Tool for screening inhibitors for the interaction of ACE2 with COV Spike protein

Biochem/physiol Actions

Angiotensin Converting Enzyme-2 (ACE2) is a membrane-associated and secreted enzyme, that is expressed predominantly on endothelium. In humans, it is highly restricted to heart, kidney, and testis.
ACE2 is a new component of the renin-angiotensin system (RAS). It provides protective effects in peripheral tissues and has great potential for the treatment of RAS-related diseases.
Coronaviruses such as SARS-CoV-2 and SARS-CoV-1 use the host ACE2 as a coreceptor to gain intracellular entry into the lungs and brain. The virion expresses a protein termed spike, which directly binds to the extracellular domain of ACE2. A specific region in the spike protein serves as the receptor binding domain (RBD). The ACE2:spike interaction has a high affinity of 15 nM.

Features and Benefits

Our biotin-tagged ACE2 enables exploration of the ACE2 interaction with Spike protein of SARS-COV-2

Unit Definition

One unit is defined as the amount of enzyme required to cleave 1 picomole of the fluorogenic peptide substrate, Mca-YVADAPK(Dnp)-OH in one minute, in 37 °C, pH 7.5.

Other Notes

This product is supplied as a powder, lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. The specific activity of recombinant ACE2 is measured by its ability to cleave a fluorogenic peptide substrate, Mca-YVADAPK(Dnp)-OH.

Legal Information

FLAG is a registered trademark of Sigma-Aldrich Co. LLC

WGK Germany

WGK 2

Certificate of Analysis

Certificate of Origin

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.